NAV

Pidilizumab

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pidilizumab
DrugBank Accession Number
DB15383
Background

Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).

Type
Biotech
Groups
Investigational
Synonyms
  • Pidilizumab

Ph值armacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
以证据为基础的和结构化的数据集。
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Ph值armacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Ph值armacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Pidilizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pidilizumab.
Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Pidilizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pidilizumab.
Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Pidilizumab.
Amivantamab The risk or severity of adverse effects can be increased when Pidilizumab is combined with Amivantamab.
Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Pidilizumab.
Ansuvimab The risk or severity of adverse effects can be increased when Pidilizumab is combined with Ansuvimab.
Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pidilizumab.
Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pidilizumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
B932PAQ1BQ
CAS number
1036730-42-3

References

一般引用
Not Available
Wikipedia
Pidilizumab

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Ph值ase Status Purpose Conditions Count
2 Completed Treatment Diffuse Large Cell Diffuse Lymphoma/Lymphoma, Mixed Cell, Diffuse/Primary Mediastinal Large B-Cell Lymphoma (PMBCL) 1
2 Terminated Treatment Stage III Diffuse Large B-Cell Lymphoma/Stage IV Diffuse Large B-Cell Lymphoma 1
1, 2 Completed Treatment Multiple Myeloma (MM) 1
1, 2 Unknown Status Treatment DIPG 1

Ph值armacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:22 / Updated at February 21, 2021 18:55